Athena Athena

X
[{"orgOrder":0,"company":"InSysBio","sponsor":"Genmab","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"InSys Bio Announces Its Collaboration with Genmab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"RUSSIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"}]

Find Clinical Drug Pipeline Developments & Deals by InSysBio

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Genmab together with BioNTech, has begun clinical development of an investigational therapy, GEN1042 (DuoBody®-CD40x4-1BB), for solid tumors. GEN1042 is a novel bispecific agonistic antibody targeting CD40 and 4-1BB for priming and activation of tumor-specific immune response.

            Lead Product(s): GEN1042

            Therapeutic Area: Oncology Product Name: GEN1042

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Genmab

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration September 23, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY